An observational study in Brain Metastases, sponsored by Sun Yat-sen University. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2022-12-15.
Sponsored by Sun Yat-sen University · Observational
The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are:
Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.
3,517 studies on the registry are indexed under Neoplasm Metastasis; 883 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 121 across 593 observational studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospital clients from Sun Yat-sen University Cancer Center, Guangxi Medical University Cancer Hospital, The People's Hospital Of Guangxi Zhuang Autonomous Region, and the First Affiliated Hospital of Guangxi Medical University will be selected.
Exclusion Criteria:
Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
Procedure: neurosurgical resection
Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group
Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group
Procedure: neurosurgical resection
Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
Procedure: neurosurgical resection
Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
Procedure: neurosurgical resection
Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group
Procedure: neurosurgical resection
neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
Also known as: radiation, chemotherapy, target therapy
OS
Overall survival time
Time frame: From date of first follow-up until the date of documented death from any cause, assessed up to 120 months
PFS
Progression-free survival time
Time frame: From date of first follow-up until the date of first documented progression, assessed up to 120 months
Plan to share: No — We decided not to share the IPD because the study involved a lot of people's privacy
No publications or documents are linked to this record.
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-sen University